Synaptogenix Inc (SNPX)

[SF Wolf]

I believe NTRP telegraphed their expectations for their upcoming AD P2b results at the recent BIO CEO and Noble Conferences. In the end there was no equivocation, no doubts, that they expect a degree of success in their Ph2b trial. I think any reasonable person listening to both recordings would come to the same conclusion.

Looking over Nuerotope’s Power Point presentation from October 2016 I noticed on Page 16 that it states “First patients dosed January 2016”.

http://www.neurotropebioscience.com/Welcome_to_Neurotrope_BioScience/Neurotrope_BioScience_files/Neurotrope%20%20100516.pdf

What that tells us is that an unknown number of advanced AD patients have already completed their Bryostatin or placebo treatments. No doubt the researchers at NTRP have seen some of the raw data, even if it was still blinded, prior to their recent public presentations.

MY PERSONAL CONCLUSION is that Neurotrope very likely has an up-and-coming AD treatment. How efficacious that treatment is we will have to wait and see.

The most up to date source of information concerning Neurotrope’s Ph2b trial is in these two very recent investor presentations. Anybody invested in NTRP or considering investing would be well served to pay careful attention:

--BIO CEO Investor Presentation on 02/13/17: https://www.veracast.com/webcasts/bio/ceoinvestor2017/18111483071.cfm

Noble Financial Capital Presentating on 1/30/17:
http://noble.mediasite.com/mediasite/Play/c54248f852db4353b8f007b16745782b1d